May 29, 2025 06:58 AM EDTUpdated 11:02 AM

PepGen ditches Duchenne programs after mid-stage fail, switches to previously halted muscle wasting therapy

Elizabeth Cairns

Senior biopharma journalist

PepGen is abandoning its exon 51-skipping Duchenne muscular dystrophy candidate after it failed a Phase 2 trial. And it is getting out of the disease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

PepGen ditches Duchenne programs after mid-stage fail, switches to previously halted muscle wasting therapy

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

Supreme Court to keep mulling state PBM dispute as US urges justices to decline case

Large pharma companies spell out reasons why tariffs will harm US investments

Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

DNA giant Illumina spawned an ecosystem of competitors and customers

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Pep­Gen ditch­es Duchenne pro­grams af­ter mid-stage fail, switch­es to pre­vi­ous­ly halt­ed mus­cle wast­ing ther­a­py

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

Supreme Court to keep mulling state PBM dis­pute as US urges jus­tices to de­cline case

Large phar­ma com­pa­nies spell out rea­sons why tar­iffs will harm US in­vest­ments

Mer­ck, Dai­ichi Sankyo scrap FDA ap­pli­ca­tion for HER3 ADC af­ter sur­vival miss

DNA gi­ant Il­lu­mi­na spawned an ecosys­tem of com­peti­tors and cus­tomers

FDA re­jects Stealth's rare dis­ease drug, but of­fers po­ten­tial for ac­cel­er­at­ed ap­proval

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

PepGen ditches Duchenne programs after mid-stage fail, switches to previously halted muscle wasting therapy

Supreme Court to keep mulling state PBM dispute as US urges justices to decline case

Large pharma companies spell out reasons why tariffs will harm US investments

Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

DNA giant Illumina spawned an ecosystem of competitors and customers

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

From weeks to days: how Aizon Intelligent Agents transform pharma validation